CYP2C19 Inhibitor Screening Assay, Catalog: MA-0390

Catalog MA-0390

Size 200 wells

Sample Type  Samples Containing Drugs, Inhibitors or Ligands (compounds that can interact and affect CYP2C19 activity).

Method of Detection Fluorometric, Ex/Em = 406/468 nm

Assay Type Quantitative

Application A simple, sensitive plate-based fluorometric assay to assess the effect of various compounds on CYP2C19 enzymatic efficiency.

Storage Conditions -20°C

Shipping Temperature Gel Pack

Shelf Life One year from the date of delivery

CYP2C19, a member of the cytochrome P450 monooxygenase family, is a membrane-bound protein which oxidatively metabolizes a range of drugs, accounting for about 10% of all commonly prescribed pharmaceuticals. Notably, clopidogrel, a prodrug, relies on CYP2C19 for activation into its pharmacologically active form, enabling inhibition of platelet aggregation. It is expressed predominantly in the liver and is highly polymorphic with at least 39 known allelic variants. Importantly these variants can exhibit a range of activity from very poor to ultrarapid, affecting how drugs are metabolized in different people. Some drugs therefore require genotyping before administration. AkrivisBio’s CYP2C19 Inhibitor Screening Kit is a simple, sensitive way to assess the effect of various compounds on its enzymatic efficiency.